Nicholas Anderson, MD
Retina Specialist · Knoxville, TNNPI 1972509297
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,855 of the $46,097 with a category attached, or 93.0%. 13 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 49.2% of the total. 2025 is the largest year on record at $19,132, 6.4 times the $2,989 reported in 2019.
Across 73 payments — averaging $631.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$23K
- Astellas Pharma US Inc$19K
- Regeneron$3K
- Deroyal Industries, Inc.$697
- Apellis Pharmaceuticals, Inc.$483
- Genentech, Inc.$233
- plus $527 from 7 others
What the payments were for
- Royalty or licence$6972%
- Consulting fees$42,85593%
- Food & beverage$2,5456%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 22 | $22,663 |
| Astellas Pharma US Inc | 7 | $18,683 |
| Regeneron | 7 | $2,810 |
| Deroyal Industries, Inc. | 6 | $697 |
| Apellis Pharmaceuticals, Inc. | 17 | $483 |
| Genentech, Inc. | 3 | $233 |
| Genentech USA, Inc. | 2 | $126 |
| Novartis | 3 | $107 |
| Astellas Pharma Global Development | 1 | $92 |
| Eyepoint US, Inc. | 1 | $83 |
| Bausch & Lomb Americas Inc. | 1 | $71 |
| Sight Sciences, Inc. | 2 | $36 |
| Rxsight Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,097 in reported general payments places this provider in the 85th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 184 | $7,772 |
| Alphagan PBrimonidine Tartrate | 17 | $4,305 |
| Brimonidine Tartrate | 40 | $3,534 |
| Ketorolac Tromethamine | 107 | $1,535 |
| MoxifloxacinMoxifloxacin Hcl | 57 | $1,206 |
| Atropine Sulfate | 24 | $795 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $291 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 18 | $214 |
| Dorzolamide Hcl | 15 | $172 |
| Timolol Maleate | 16 | $75 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Knoxville
- Timothy StoutKnoxville$13K
- Jacob CoxKnoxville$6K
- Jonathan FuerstKnoxville$3K
- Robert ShulerKnoxville$3K
- James MillerKnoxville$3K
- Joseph GoogeKnoxville$2K
- Stephen PerkinsKnoxville$2K
- Ailee LahamKnoxville$2K
- Tod McMillanKnoxville$850
- Steve CharlesGermantown$5.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.